Introduction {#Sec1}
============

Inborn errors of metabolism (IEMs) form a large class of genetic diseases involving congenital disorders of metabolism. The majority are due to defects of single genes that code for enzymes that facilitate conversion of substrates into products. Although individual IEMs are rare, collectively they represent a large and diverse group of diseases. The majority of IEMs has a prevalence of less than 10 per 100,000 births with a total prevalence of all IEMs reaching 40 per 100,000 births, although the prevalence varies considerably worldwide based on the racial and ethnic composition of the population. From a societal point of view IEMs are an important burden of the medical care systems in Western countries where the most common communicable diseases are eradicated.

Although several approaches are used to treat patients with an IEM, they all have the common goal to overcome the biochemical aberrations caused by the primary enzyme defect. Therefore, understanding of the molecular and biochemical etiologies of the many IEMs is essential for successful treatment of these patients. Flux analyses by stable isotope methodology forms an important modality in the study of IEMs.

When an enzyme is deficient, metabolism seeks a new steady state, away from its physiological homeostasis. A new balance of fluxes associated with the consumption and production of metabolites characterizes the new steady state. A flux is the actual flow of metabolites through a metabolic pathway and is determined by both the rate of supply of substrates and the capacity of that pathway to convert them into products. Hence, neither changes in concentrations of intermediates nor changes in enzyme concentrations and/or activities of the reprogrammed metabolism separately hold information on the changes of the distribution of fluxes. The question arises of how to measure these changes. This review focuses mainly on studies applying stable isotope technology with mass spectrometric detection of mass isotopomer distributions (MID) of metabolites after separation by chromatography. In the next section, a short overview of the relevant stable isotope technology will be given followed by a discussion of the experimental studies over the last decades of a selected group of IEM; glycogen storage disease type I (GSD I), medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, propionic aciduria (PA) and methylmalonic aciduria (MMA), urea cycle defects (UCD), phenylketonuria (PKU) and combined D,L-2-hydroxyglutaric aciduria. An earlier discussion of the application of stable isotopes in IEM can be found in Eur J Pediatr 156 Supplement 1 (1997).

Methods of stable isotope tracer technology used in studies of flux analysis in IEM {#Sec2}
===================================================================================

Isotope dilution of an exogenous infused metabolite {#Sec3}
---------------------------------------------------

Two applications of stable isotope tracer studies have been used most often in the field of inborn errors of metabolism, isotope dilution of an exogenous infused labeled metabolite (this section) and isotope dilution of an endogenous produced metabolite (next section). For our discussion of the application of stable isotopes two assumptions will be essential: (i) metabolism of labeled tracer and unlabeled tracee is indistinguishable and (ii) metabolism of tracee and tracer is at steady state. At steady-state no changes occur in the concentrations of tracer and tracee. Hence, rate equations reduce to algebraic equations, which can be solved easily. Moreover, at steady state the rate of production of the metabolite of interest equals the rate of its consumption. When the aim of a study is to estimate the rate of appearance of a metabolite (R~a~) in vivo in animals or humans, an experiment can be performed in which a solution of an isotopically labeled compound (tracer) is intravenously infused and the dilution of the tracer by the tracee is measured in the circulation. To keep the discussion clear, the estimation of the rate of appearance of glucose into the systemic circulation will serve as an illustration. A solution of stable isotope labeled glucose is continuously infused intravenously at a rate V~inf~ into the systemic circulation of the animal or human. Suppose glucose is labeled at all six carbon atoms with ^13^C (a.k.a. uniformly labeled glucose, \[U-^13^C\]-glucose). At different time points blood samples are drawn and after work-up of the samples the MID of glucose at the various time points is measured by gas chromatography coupled to mass spectrometry. Only the time points at isotopic steady-state will be used. Next the measured intensities are normalized to the sum of the intensities of all mass isotopomers comprising the measured MID and the relative contributions are calculated for glucose molecules labeled with no ^13^C atom (m~0~), 1 ^13^C atom (m~1~), 2 ^13^C atoms (m~2~) till 6 ^13^C atoms (m~6~) with $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\sum}_{\mathrm{i}=1}^6{\mathrm{m}}_{\mathrm{i}}=1 $$\end{document}$. Carbon is naturally enriched with ^13^C (about 1.07 % (Meija et al [@CR61])); therefore, the recorded MID contains glucose molecules labeled by natural enrichment and by the infused \[U-^13^C\]-glucose. After correction of the recorded MID for natural enrichment of ^13^C (Midani et al [@CR63]) the corrected MID (M~0~ -- M~6~ with $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\sum}_{\mathrm{i}=1}^6{\mathrm{M}}_{\mathrm{i}}=1 $$\end{document}$) is solely determined by the dilution of labeled glucose ($\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {M}_6^{glc} $$\end{document}$*(infuse)*) by unlabeled glucose entering the systemic circulation. Since measurements at steady-state are used, R~a~ can be calculated in two steps; (i) the total rate of appearance (R~a~(tot)) of glucose is calculated by Eq.[1](#Equ1){ref-type=""} and (ii) R~a~(tot) is corrected for the rate of infusion of labeled glucose (V~inf~) according to Eq.[2](#Equ2){ref-type=""} to obtain the rate of appearance (R~a~) of unlabeled glucose:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\mathrm{R}}_{\mathrm{a}}^{\mathrm{glc}}\left(\mathrm{tot}\right)=\frac{{\mathrm{M}}_6^{\mathrm{glc}}\left(\mathrm{infuse}\right)}{{\mathrm{M}}_6^{\mathrm{glc}}\left(\mathrm{blood}\right)}\times {\mathrm{V}}_{\mathrm{inf}}, $$\end{document}$$with $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \frac{M_6^{glc}(infuse)}{M_6^{glc}(blood)} $$\end{document}$ is the dilution of the tracer \[U-^13^C\]-glucose by the tracee unlabeled glucose and$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {\mathrm{R}}_{\mathrm{a}}^{\mathrm{glc}}={\mathrm{R}}_{\mathrm{a}}^{\mathrm{glc}}\left(\mathrm{tot}\right)\hbox{-} {\mathrm{V}}_{\mathrm{inf}} $$\end{document}$$

It should be realized that the calculated rate of appearance represents the flux through the studied pool (in our case, glucose in the systemic circulation) at the steady state studied and does not give information on the total capacity of the metabolic pathway, nor on the flux at a different steady state.

Isotope dilution of an endogenously produced metabolite {#Sec4}
-------------------------------------------------------

Let us now consider the appearance of glucose in the circulation during fasting with contributions of glycogenolysis and gluconeogenesis. When one of these processes can be estimated independent from the other, we gain information on how the appearance of glucose is determined by these two processes. To this purpose Hellerstein and coworkers developed an approach to estimate the rate of gluconeogenesis by a method they named mass isotopomer distribution analysis (MIDA) (Hellerstein and Neese [@CR30]). Kelleher and coworkers developed a similar approach, which they named isotopomer spectral analysis (Kelleher and Masterson [@CR48]; Kelleher and Nickol [@CR49]; Tredwell and Keun [@CR91]). During gluconeogenesis glucose is made from fructose-1,6-bisphosphate (Frc-1,6-P~2~), which is the product of the condensation of dihydroxyacetonphosphate (DHAP) and glyceraldehyde-3-phosphate (GA3P) by aldolase (Fig. [1](#Fig1){ref-type="fig"}). In vivo labeling of DHAP and GA3P is accomplished by intravenous infusion of a solution containing \[2-^13^C\]-glycerol and this will never result in complete labeling of the intracellular pools of DHAP and GA3P. Therefore, unlabeled DHAP and GA3P will always be present. Hence, condensation of labeled and unlabeled DHAP and GA3P randomly selected by aldolase will result in a mixture of labeled and unlabeled Frc-1,6-P~2~ and subsequently of labeled and unlabeled gluconeogenic glucose. When unlabeled DHAP condenses with unlabeled GA3P, it results in unlabeled M~0~ Frc-1,6-P~2~, unlabeled DHAP with labeled \[2-^13^C\]-GA3P results in single labeled M~1~ Frc-1,6-P~2~, similar to the condensation of labeled \[2-^13^C\]-DHAP with unlabeled GA3P and labeled \[2-^13^C\]-DHAP with labeled \[2-^13^C\]-GA3P results in double labeled M~2~ Frc-1,6-P~2~. The higher the enrichment of DHAP and GA3P, the higher will be the contribution of M~2~ Frc-1,6-P~2~ (compare Fig. [1](#Fig1){ref-type="fig"}a with Fig. [1](#Fig1){ref-type="fig"}b). When this set of unlabeled and labeled Frc-1,6-P~2~ is converted into glucose, it will be diluted by unlabeled glucose-6-phosphate (G6P) released by glycogenolysis. Thus, unlabeled glucose not only arises from gluconeogenesis because of the incomplete labeling of the monomeric pool of triose-phosphates but also from glycogenolysis. To correct for the synthesis of unlabeled glucose by gluconeogenesis, Hellerstein and coworkers treated gluconeogenesis as a kind of 'polymerization' reaction, with glucose as a 'dimer' of the monomer triose-phosphate (Hellerstein and Neese [@CR30]) (Fig. [1](#Fig1){ref-type="fig"}c). The MID of labeled glucose can then be described by a frequency distribution of two monomers, labeled and unlabeled triose-phosphate. The mass isotopomers M~1~ and M~2~ of glucose are used to calculate the triose-phosphate enrichment. Next, this calculated triose-phosphate enrichment is used to calculate the 'true' MID (M~0~-M~2~) of newly synthesized glucose. This 'true' MID ('tracer') is compared to the measured MID of glucose ('tracee') in the circulation to calculate the degree of dilution of gluconeogenic glucose. In this way, Eq. [1](#Equ1){ref-type=""} can be applied to calculate the rate of gluconeogenesis *V*~*gng*~. $\documentclass[12pt]{minimal}
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                \begin{document}$$ {M}_1^{glc}(blood) $$\end{document}$, the measured fraction of M~1~ glucose in the circulation and *V*~*inf*~ is replaced by *V*~*gng*~, the parameter to be calculated. R~a~, the rate of glucose appearance into the systemic circulation is measured separately by isotope dilution of \[U-^13^C\]-glucose. In this way the 'true' *V*~*gng*~ can be calculated. By subtraction of V~gng~ from R~a~ of glucose the rate of glycogenolysis is obtained.Fig. 1Schematic representation of 'dimerization' of triose-phosphates in the gluconeogenic synthesis of glucose. **a** Dimerization of triose-phosphates at low enrichment of triose-phosphate pool; **b** Dimerization of triose-phosphates at high enrichment of triose-phosphate pool; **c** The equations used to calculate the triose-phosphate enrichment from the observed MID of glucose and the 'true' MID of newly synthesized glucose; **d** The theoretical MID at different enrichments of the triose-phosphate pool. Blue circles represent unlabeled triose-phosphate molecules, red circles represent labeled triose-phosphate molecules, and connected circles represent glucose molecules, with all blue M~0~, single red M~1~, and double red M~2~ mass isotopomers

Labeling of the triose-phosphate pool can also be achieved by infusing appreciable amounts of \[U-^13^C\]-glucose, which results in labeling of the triose-phosphate pool. Extensive metabolism of glucose by glycolysis, TCA cycle, and gluconeogenesis gives rise to M~0~ -- M~3~ triose-phosphate and M~0~ -- M~6~ glucose. This phenomenon is referred to as 'scrambling' of the glucose label.

MIDA can also be used to estimate de novo lipogenesis in vivo. During de novo synthesis of palmitate, FASN concatenates eight acetate molecules. Palmitate can thus be considered an 'octamer' of the monomer acetate. In in vivo experiments infusion of \[2-^13^C\]-acetate labels the intracellular pool of acetate used for lipogenesis only moderately, and labeled and unlabeled acetate will be incorporated into palmitate. Hence, newly synthesized palmitate consists of a mixture of labeled and unlabeled molecules. Unlabeled palmitate is a mixture from preexisting and lipogenic palmitate. Similar to the case of glucose, these two sources of unlabeled palmitate can be distinguished by MIDA. The MID of newly synthesized palmitate can be described by a frequency distribution of an octamer with two monomers, labeled and unlabeled acetate. The enrichment of acetate is calculated from the measured mass isotopomers M~1~-M~8~ of labeled palmitic acid. Next, the 'true' MID of newly synthesized palmitate (M~0~ -- M~8~) is calculated. The measured MID (M~0~ -- M~8~) of palmitate, in for instance VLDL, reflects the dilution of the newly synthesized palmitate by existing palmitate. The rate of de novo lipogenesis is estimated with Eq. [1](#Equ1){ref-type=""}, when the rate of appearance of palmitate into the studied pool is accessible for measurements. Otherwise, only the fraction of newly synthesized palmitate can be estimated. Oosterveer et al ([@CR71]) extended the method to calculate the degree of chain-elongation of palmitate into stearate and oleate.

In summary, in the case of a 'polymerization' reaction, a decrease in label incorporation into products can be due to (i) a decrease in enrichment of the monomers without a change in dilution of the newly synthesized product or (ii) a greater dilution of the newly synthesized product but with the same enrichment of the monomers. In the first case the MID of the labeled product will shift to lower mass isotopomers, in the latter case the relationship between the ^13^C--labeled product mass isotopomers (M~1~-M~i~) remains the same but the abundances of the mass isotopomers of the labeled product (M~1~-M~i~) decrease compared to the unlabeled product (M~0~).

Oral loading tests {#Sec5}
------------------

Oral loading tests are used to evaluate the degree of impairment of metabolism due to the deficiency of a particular enzyme in a non-invasive manner. In an oral loading test a labeled precursor is given and the degree of transfer of the label to a metabolic end-product is measured. In a breath test, an oral bolus of a ^13^C--labeled precursor is given and the enrichment of ^13^CO~2~ is measured. It is assumed that in this way the rate of oxidation of the substrate can be estimated. Similarly, when an oral bolus of ^15^NH~4~CO~3~ is given and the enrichment of \[^15^N\]-urea is measured it is assumed that the rate of urea synthesis in vivo can be estimated. Although simple to perform, these tests suffer from serious drawbacks. Very appreciable variation in test outcome is observed due to unknown dilution of the labeled precursor by metabolism in the studied subjects and by bacterial metabolism in the intestinal tract, unknown dilution of the end product, particularly when ^13^CO~2~ is used (Veeneman et al [@CR99]), incomplete recovery of the isotope given and poor repeatability of tests (Kalivianakis et al [@CR45]). It is for these reasons that we concluded that oral loading tests with label transfer into metabolic end products are of limited use for the quantitative assessment of the flux through the metabolic pathway under study (Reijngoud and Verkade [@CR75]). Therefore, the oral loading test will not be discussed.

Irrespective of this conclusion, an interesting approach might be the use of \[1-^13^C\]-acetate to measure the residual activity of the urea cycle in patients with a urea cycle defect (Yudkoff et al [@CR114]). Besides the appearance of ^13^C in urea, these authors also measured the enrichment of ^13^CO~2~ in exhaled air. When the changes of the enrichment of ^13^C in urea were corrected for the changes of the enrichment of breath ^13^CO~2~, the authors were able to calculate a urea cycle activity in a control subject not different from the values obtained by a primed-continuous infusion protocol (see Urea cycle defects section for discussion).

Experimental studies {#Sec6}
====================

Glycogen storage disease type I {#Sec7}
-------------------------------

### Residual glucose production in patients with GSD Ia in vivo {#Sec8}

The measurement of glucose production in patients GSD I (MIM\# 607008) has been pursued over many decades (see Fig. [2](#Fig2){ref-type="fig"} for a timeline) by isotope dilution of various stable isotope labeled glucose molecules. In GSD I the conversion of glucose-6-phosphate (G6P) into glucose by the glucose-6-phosphatase complex (G6Pase) (EC\# 1.3.8.7) is deficient. Hence, G6P generated by gluconeogenesis and glycogenolysis cannot be converted into glucose. This prevents gluconeogenic organs, mainly liver, to produce glucose when the prandial release of glucose by the intestine dwindles down and finally stops. One expects that in these patients no endogenous glucose production could exist. Quite to the contrary, several studies applying dilution of infused stable isotope labeled glucose have shown that in these patients an appreciable glucose production exists. The measurement of the rate of appearance of glucose in GSD Ia patients started in 1984 with a study by Tsalikian et al ([@CR92]). Five children with GSD I were infused with \[6,6-^2^H~2~\]-glucose intravenously and the isotope dilution of \[6,6-^2^H~2~\]-glucose in blood samples drawn at isotopic steady state was measured. The endogenous glucose production equaled 21.4 ± 0.2 μmol.kg^−1^.min^−1^, considerably less than in unaffected children (34.6 ± 0.2 μmol.kg^−1^.min^−1^), but still appreciable (\~60% of control). They also measured the endogenous glucose production while the infusion rate of exogenous unlabeled glucose was increased stepwise. At the highest exogenous glucose infusion rate of 33.3 μmol.kg^−1^.min^−1^ endogenous glucose production could still be measured, although the rate was decreased to 7.1 ± 0.4 μmol.kg^−1^.min^−1^. Comparable observations were made by Wengler et al ([@CR107]) and Huidekoper et al (Huidekoper et al [@CR36]). Kalderon and coworkers (Kalderon et al [@CR42], Kalderon et al [@CR44], Kalderon et al [@CR43]) studied glucose production with \[^13^C~6~\]-glucose and measure isotope dilution and 'scrambling' of ^13^C--labeling in glucose by NMR. They also showed that GSD I patients produced glucose, and that the rate was lower than in healthy subjects. However, in contrast to healthy subjects, essentially no 'scrambling' of \[U-^13^C\]-glucose was observed. Jones et al ([@CR41]) measured gluconeogenesis and anaplerosis of the TCA cycle in five fed healthy subjects and five GSD Ia patients on cornstarch therapy. All subjects received a dose of acetaminophen, phenylbutyrate, and \[U-^13^C\]-glycerol. Blood and urine samples were collected and label distributions were measured by NMR of glucose in plasma and of the glucuronate residue of acetaminophen glucoronate, reflecting G6P labeling, and of the glutamine residue in N-phenylacetylglutamine, reflecting 2-ketoglutarate labeling. In healthy subjects 35 ± 14% of plasma glucose originated from hepatic G6P, while in patients no detectable contribution of G6P to plasma glucose was observed. Moreover, in GSD1a patients, labeling pattern in the glutamine residue of N-phenylacetylglutamine pointed to a redirection of the fluxes through the Krebs cycle to dispose of carbon normally used in gluconeogenesis to lactate production.Fig. 2Timeline of measurements of endogenous glucose production in GSD I patients and development of model systems in mice. The references mentioned are (Powell et al [@CR73]), (Tsalikian et al [@CR92]), (Kalderon et al [@CR42]), (Rother and Schwenk [@CR79]), (Lei et al [@CR53]), (van Dijk et al [@CR93]), (Weghuber et al [@CR107]), (Jones et al [@CR41]), (Huidekoper et al [@CR36]), (Mutel et al [@CR65]) (Hijmans et al [@CR33])

Collectively, these studies proved the existence of an endogenous glucose production in children with GSD I that even responded to exogenous glucose infusion. A process fundamentally different from gluconeogenesis, however, sustains the endogenous glucose production in GSD I patients. Moreover, metabolism of pyruvate was reprogrammed with a shift from anaplerosis to lactate production.

### Glucose metabolism in animal models of GSD Ia and Ib {#Sec9}

Tsalikian et al ([@CR92]) hypothesized that glucose production in GSD Ia could be driven by the glucosidase activity of debranching enzyme or lysosomal α-glucosidase after autophagy of glycogen (a.k.a. glycophagy, (Jiang et al [@CR39])). These hypotheses are difficult to reconcile with the intracellular presence of glucokinase/hexokinase, which will most likely rapidly convert intracellularly released glucose into G6P. The question arises, however, of whether hepatic metabolism of G6P in GSD I is still comparable to that in healthy controls. Van Dijk et al ([@CR93]) published a series of experiments on glucose metabolism in rats acutely treated with S4048, an inhibitor of G6P transporter, mimicking GSD Ib (Fig. [3](#Fig3){ref-type="fig"}). They used the isotopic model of Hellerstein (Hellerstein et al [@CR31]) to study the rearrangement of the flux distribution around G6P during an infusion of S4048 (Fig. [3](#Fig3){ref-type="fig"}a). Conscious and freely moving rats were infused with a multi tracer solution of \[U-^13^C\]-glucose, \[2-^13^C\]-glycerol, \[1-^2^H\]-galactose, acetaminophen, and when necessary S4048. During infusion blood samples were drawn and timed urine samples were collected. Label distributions were measured in glucose in plasma and the glucuronide moiety of acetaminophen glucuronic acid in urine. The label distribution in the glucuronide moiety of acetaminophen-glucuronate reflects the label distribution in the glucose moiety of UDP-glucose, which is in rapid equilibrium with G6P. In this isotope model the following fluxes are measured: (i) whole body glucose production, by dilution of infused \[U-^13^C\]-glucose, (ii) the glucokinase flux by the appearance of the label of \[U-^13^C\]-glucose in the glucuronide moiety of acetaminophen-glucuronate, (iii) gluconeogenesis, by \[2-^13^C\]-glycerol incorporation into glucose and glucose moiety of acetaminophen glucuronic acid, (iv) glycogen synthesis, by dilution of \[1-^2^H\]-galactose in the glucuronide moiety of acetaminophen glucuronic acid, (v) the G6Pase flux by the appearance of label from \[1-^2^H\]-galactose in glucose in plasma. Assuming flux balance at G6P all fluxes in this model can be calculated. At an infusion rate of S4048 of 0.53 ± 0.03 mg.kg^−1^.min^−1^ the G6Pase flux decreased by 50% (Fig. [3](#Fig3){ref-type="fig"}b). Intracellular concentration of G6P increased from 0.5 ± 0.1 to 2.7 ± 0.3 μmol.(g liver wet weight)^−1^. The rate of glycogenesis increased as expected in view of the increased G6P concentrations. Quite strikingly, glucokinase flux was almost abolished. It was hypothesized that the high intracellular concentrations of G6P increased fructose-6-phosphate which inhibited glucokinase activity by the stimulation of the formation of the inhibitory complex of glucokinase and glucokinase regulatory protein (see (Lenzen [@CR54]) for a review). Hence, cytosolic glucose, released by debranching enzyme or lysosomal α-glucosidase could escape phosphorylation and be transported into the systemic circulation.Fig. 3Effects of S4048 treatment in fasted rats on the fluxes through hepatic carbohydrate pathways. **a** Schematic representation of the major metabolic pathways considered in the model of hepatic carbohydrate metabolism of Hellerstein et al ([@CR31]). The pathways included are: gluconeogenesis (de novo synthesis of G6P from pyruvate); glycogenolysis; G6Pase; glucosekinase; and glycogenesis. Infused labeled metabolites are presented in blue, sampling sites and the sampled compounds are presented in red. S4048 inhibits G6P to glucose pathway. **b** The values obtained for the fluxes through the pathways depicted in (**a**) in vehicle-treated (gray bars) and S4048 treated rats (black bars). (*n* = 3) Source: (van Dijk et al [@CR93]), *reproduced with permission from the American Society of Biochemistry and Molecular Biology*

The generation of mice with a liver specific G6Pc knockout offers new possibilities to study metabolic mechanisms more closely underlying the endogenous glucose production (Mutel et al [@CR65]). Very recently, Hijmans et al ([@CR33]) applied the above described model of hepatic glucose metabolism to study glucose metabolism in these mice (Fig. [4](#Fig4){ref-type="fig"}a). They showed by in vivo analysis of hepatic glucose metabolism in these mice that the hepatic glucokinase flux was decreased by 95% in L-*G6pc−/−* mice (Fig. [4](#Fig4){ref-type="fig"}b). Glycogen synthase flux and phosphorylase flux were increased, resulting in an almost tenfold increase in cycling of the glucose moiety in UDP-glucose (Fig. [4](#Fig4){ref-type="fig"}b-e) in L-*G6pc−/−* mice. As a consequence, this gave rise to a tenfold increase of the release of free glucose via glycogen debranching. Furthermore, the authors showed that pharmacological inhibition of α-glucosidase activity by deoxynojirimycin almost abolished the residual glucose production in isolated *G6pc*-deficient primary hepatocytes. In conclusion, glucosidase activity sustains the glucose production in GSD Ia patients. Glucose phosphorylation is strongly suppressed. When patients with GSD Ia were treated with a glucose infusion or continuous glucose supply from cornstarch, glucose production decreased (Tsalikian et al). Hijmans et al ([@CR33]) proposed that increased exogenous glucose supply might reactivate glucokinase. Subsequently, intracellular released glucose by glucosidase activity will be phosphorylated and glucose appearance in the circulation will decrease.Fig. 4Hepatic carbohydrate metabolism in mice with a liver-specific knock-out of G6Pc. (**a**) Schematic representation of the model of hepatic carbohydrate metabolism. The red arrow indicates the liver-specific knockout of G6Pc. see legend of Fig. [3](#Fig3){ref-type="fig"}a for explanation. Figures [3](#Fig3){ref-type="fig"}(**b**), (**c**), (**d**), (**e**) show the boxplots of the flux through glucokinase, UDP-glucose cycling, glycogen synthase, and glycogen phosphorylase, respectively, with L-G6Pc^+/+^ mice (white boxes) (*n* = 6) and L-G6Pc−/− mice (black boxes) (n = 6). Values are depicted as boxplots with middle line: median, box: 25th to 75th percentiles and whiskers: 5th and 95th percentiles for n = 6 per group. *\*P* \< 0,05. Source: (Hijmans et al [@CR33]), *reproduced with permission from the American Association of the Study of Liver Diseases*

### Lipid metabolism in patients with GSD Ia in vivo {#Sec10}

In GSD I patients lipid metabolism is severely perturbed. GSD Ia patients suffer from a combined hypertriglyceridemia and hypercholesterolemia. In a preliminary study de novo lipogenesis and cholesterol synthesis were measured in two GSD Ia patients by the infusion of \[2-^13^C\]-acetate, the measurement of the incorporation of ^13^C label in palmitate in VLDL and the analysis of the data by MIDA (Bandsma et al [@CR8]). Both rates were strongly elevated. Later Bandsma et al ([@CR7]) extended these studies and included the rate of VLDL synthesis by the incorporation of infused \[1-^13^C\]-valine into apoB100. The results showed de novo lipogenesis was enhanced in GSD Ia patients confirming earlier results. The results of the incorporation of \[1-^13^C\]-valine into apoB100 showed that the rate of VLDL synthesis was not affected. In view of these results the authors hypothesized that lipolysis in GSD Ia patients must be impaired.

### Lipid metabolism in animal model of GSD Ib {#Sec11}

These results of lipid metabolism in GSD I patients were partially reproduced in rats treated with S4048 (Bandsma et al [@CR6]). Acute inhibition of the G6P translocator led to a tenfold increase in de novo lipogenesis, albeit cholesterol synthesis remained unaffected. Levels of triglyceride in blood rose almost twofold during an 8 h infusion of rats with S4048, while VLDL production was not affected. Apparently, VLDL lipolysis must have been impaired. These metabolic changes were accompanied by increased expression of the genes encoding FASN and ACAT1. The enhanced expression turned out to be driven by ChREBP, a nutrient sensing-transcription factor activated by G6P, among other sugar-phosphates (Richards et al [@CR77]). When whole body ChREBP knockout mice were treated with S4048 the increase in expression of the genes encoding FASN and ACAT1 was abolished (Grefhorst et al [@CR25]).

In conclusion, metabolic reprogramming in GSD I resulted in an endogenous glucose production by an alternative pathway mediated by the glucosidase activity of glycogen debranching enzyme and/or lysosomal glycogen degradation. Phosphorylation of glucose was almost abolished. De novo lipogenesis and cholesterol synthesis were increased. VLDL production was not affected. Lipid levels in blood were increased, which pointed to impaired lipolysis. These changes appeared to be brought about by an active and regulated process mediated in part by G6P activated ChREBP.

Medium-chain acyl-CoA dehydrogenase deficiency {#Sec12}
----------------------------------------------

### Residual activity of mitochondrial medium-chain fatty acid oxidation in patients with MCAD deficiency in vivo {#Sec13}

Heales et al measured the rate of oxidation of \[1-^13^C\]-octanoate in patients with MCAD (EC\# 1.3.8.7) deficiency (MIM\# 607008) (Heales et al [@CR29]). They used a primed-continuous intravenous infusion of \[1-^13^C\]-octanoate for 4 h in four patients with MCAD deficiency after an overnight fast. The rate of appearance calculated according to Eqs. ([1](#Equ1){ref-type=""}) and ([2](#Equ2){ref-type=""}) ranged from 14.7 to 36.2 μmol.kg^−1^.min^−1^. Moreover, near normal values were observed for the oxidation of octanoate in these patients, varying between 6.4 and 13.1 μmol.kg^−1^.min^−1^. On average 40.0% of the infused octanoate was oxidized. The metabolic fate of the remaining 60% of the infused labeled octanoate was not reported.

It has been hypothesized that ketogenesis is impaired in patients with MCADD. Fletcher and Pitt ([@CR23]) measured the rate of ketogenesis in three well children with MCADD after 9 to 11 h fasting before starting the study period. They used a primed-continuous infusion protocol of the sodium salts of \[1,3-^13^C~2~\]-acetoacetate and \[1,2,3,4-^13^C~4~\]-3-hydroxybutyrate. They applied the two-accessible pool model to estimate the rates of ketogenesis, interconversions, and ketone utilization (Bougneres et al [@CR12]). When compared to the rates in six healthy children (Bougneres and Ferre [@CR13]) no differences were observed between healthy and affected children. Apparently, in these well children, ketogenesis was not impaired.

### Animal models of mitochondrial fatty acid oxidation defects {#Sec14}

Flux analysis of metabolism in various models of mitochondrial fatty acid oxidation (mFAO) defects has mainly been focused on the consequences of these defects on glucose metabolism. Patients with a defect of mFAO suffer from acute, life-threatening episodes of hypoglycemia. The acute effects of CPT-I inhibition by 2-tetradecylglycidic acid (TDGA) on glucose metabolism have been studied in mice (Fig. [5](#Fig5){ref-type="fig"}) (Derks et al [@CR21]). The authors applied the isotopic model of hepatic glucose metabolism and the multiple tracer infusion and sampling protocol as described above, with timed urine samples collected at hourly intervals on filter paper and without the inhibitor of the G6P transporter (Fig. [5](#Fig5){ref-type="fig"}a). Short term fasted mice received a single injection of a bolus of TDGA 9 h before the start of the experiment. At the start of the experiment, the injected mice suffer from hypoglycemia in contrast to vehicle treated mice. Changes in hepatic glucose metabolism were subtle, with a small decrease in gluconeogenesis, glycogen synthesis, and glucose phosphorylation. Irrespective of the hypoglycemia glucose production remained unaffected. In contrast, metabolic clearance rate of glucose increased considerably from \~17 ml.kg^−1^.h^−1^ to \~28 ml.kg^−1^.h^−1^. The cause of the inadequate rate of gluconeogenesis was not clear. Later studies in mice with a knockout of long chain-acylCoA dehydrogenase (Houten et al. [@CR35]) also observed no increase in gluconeogenesis irrespective of low blood glucose concentrations in fasted mice, applying the same methodology as in the study with MCAD knockout mice. When in a separate experiment an oral bolus of alanine was given, blood glucose concentration increased transiently, indicating a possible short supply of gluconeogenic substrates. This observation has not been followed up by a stable isotope experiment to estimate gluconeogenesis in the presence of an alanine infusion. At this moment it remains an open question whether delivery of gluconeogenic substrates by peripheral tissue is hampered resulting in an inadequate rate of gluconeogenesis.Fig. 5Effects of 2-tetradecylglycidic acid (TDGA) treatment on hepatic carbohydrate metabolism in mice. Mice were injected with vehicle (controls) or 30 mg/kg TDGA intraperitoneally and fasted for 9 h. Subsequently, the 6-h infusion experiment was performed. White bars show results in vehicle-treated mice, black bars in TDGA-treated mice. Data are presented as mean ± SEM, *n* = 6. \**P* \< 0.05. Source: (Derks et al [@CR21]), *reproduced with permission from the American Association for the Study of Liver Disease*

The effects of MCAD deficiency on glucose metabolism in vivo (Herrema et al [@CR32]) were studied in mice with a deletion of MCAD (Tolwani et al [@CR90]) by the same methods as described above. In vivo glucose metabolism was hardly affected in the mice with MCAD knocked out (Fig. [6](#Fig6){ref-type="fig"}). Only glycogen metabolism changed, while glucose production decreased slightly. Lipopolysaccharide (LPS) was used in an effort to mimic in MCAD^−/−^ mice the sudden deterioration of the clinic of MCAD deficient patients. A single bolus of LPS, to induce an acute phase response, resulted in a decreased blood glucose concentration from 6.2 ± 0.5 to 2.5 ± 0.5 mM in MCAD^−/−^ mice, not different form WT mice (8.2 ± 0.2 to 3.0 ± 0.5 mM). Glucose phosphorylation decreased more strongly after administration of LPS in MCAD^−/−^ mice compared to WT mice. Moreover, the flux through gluconeogenesis decreased in MCAD^−/−^ mice, even with the low glucose concentrations in blood.Fig. 6Effects of lipopolysaccharide (LPS) treatment in MCAD-deficient mice. Wild-type and MCAD−/− mice were injected with saline (-LPS) or LPS (+LPS) followed by a 9-h fast. The 6-h infusion experiment was performed subsequently. Graphs on each arrow represent the flux of the pathways as explained in Fig. [3](#Fig3){ref-type="fig"}. White bars show results in wild-type mice, black bars in MCAD--/-- mice. Data are presented as the mean ± SEM, *n* = 6. ^\#^*P* \< 0.05 between groups. \**P* \< 0.05 within groups. Source: (Herrema et al [@CR32]), *reproduced with permission from the American Association for the Study of Liver Disease*

Until now, these studies have not been able to give us detailed information on the mechanisms underlying the clinical course of patients with a mFAO defect. Recently, the group of Bakker and coworkers developed a kinetic model of the mFAO (van Eunen et al [@CR94], van Eunen et al [@CR95], Martines et al [@CR58]). Simulations of the rate of oxidation of palmitoyl-CoA at increasing concentrations of palmitoyl-CoA showed that the 'circular' organization of the mFAO pathway with promiscuous enzymes resulted in a sudden and rapid decrease of the rate of the mFAO at high concentration of palmitoyl-CoA. The flux through mFAO 'collapsed' because the activity of medium-chain ketoacyl-CoA thiolase rapidly deteriorated upon approaching the point of 'collapse' (Martines et al [@CR58]). Concomitantly, free CoASH concentration decreases to very low values because of the accumulation of acyl-CoA intermediates. When MCAD was eliminated from the model, the initial rate of palmitate oxidation did not differ from the rate calculated with MCAD present. However, the point of 'collapse' was reached at far lower concentrations of palmitoyl-CoA. One should be aware that very low free CoASH concentrations in mitochondria also severely interfere in pyruvate decarboxylation and TCA cycle activity. This can result in an overall impairment of the mitochondrial function. This sequence of events might take place in febrile MCADD patients upon fasting. Then metabolic demands are high and concentrations of free fatty acids in the circulation are high. In this respect it is of interest to note that MCAD can play a role in the detoxification of xenobiotic arylcarboxylates released by gut microbial metabolism. Products of microbial metabolism in the gut, like phenylpropionate and phenylbutyrate, are used as substrates in the activity assay of MCAD (Rinaldo et al [@CR78], Derks et al [@CR20], Kormanik et al [@CR51]). Impaired metabolism of the CoA thio-esters of arylcarboxylates might trap free CoASH in mitochondria. The point of 'collapse' of fatty acid oxidation will then be reached at low concentrations of long-chain acyl-CoA. Hence, when MCAD is deficient the mFAO becomes vulnerable for rapid sequestration of free CoASH already at low concentrations of fatty acid with a sudden decrease in the rate of fatty acid oxidation as a result.

Next to mitochondria, peroxisomes contribute significantly to the oxidation of long-chain fatty acids (Wanders et al [@CR104], Wanders [@CR102]). The partitioning of the oxidation of fatty acids of various chain-lengths over peroxisomes and mitochondria was studied in isolated non-recirculating isolated rat heart and liver perfusion by the group of Brunengraber and coworkers (Reszko et al [@CR76], Bian et al [@CR10], Kasumov et al [@CR46]). They studied the fate of \[1-^13^C\]-C~21:0~-n-, \[1-^13^C\]-C~18:1~-n-, \[1-^13^C\]-C~8:0~-n-, \[3-^13^C\]-C~8:0~-n-, \[1-^13^C\]-C~6:0~-n-, \[1-^13^C\]-C~4:0~-n-carboxylic acid, \[1,2-^13^C~2~\]-acetate and \[1,12-^13^C~2~\]-C~12:0~-n-dicarboxylic acid. They used the ^13^C--labeling ratio of malonyl-CoA enrichment over the enrichment of the acetate moiety of citrate to estimate the partitioning of fatty acids over peroxisomal FAO (pFAO) and mFAO. The observed ^13^C--labeling ratios indicated that, as expected, long-chain fatty acids were oxidized in mitochondria. However, concomitantly, they were vividly oxidized in peroxisomes till C~6:0~-n-carboxylic acid, followed by oxidation in mitochondria. This became clear when the ^13^C--labeling ratios were compared when \[1-^13^C\]-C~8:0~-n-carboxylic acid was infused with the ratio when \[3-^13^C\]-C~8:0~-n-carboxylic acid was infused. Only \[1-^13^C\]-C~8:0~-n-carboxylic acid resulted in a ^13^C--labeling ratio indicative of both pFAO and mFAO. Oxidation of \[3-^13^C\]-C~8:0~-n-carboxylic acid resulted in ^13^C labeling ratios indicative of mFAO. Transfer of ^13^C from \[1,12-^13^C~2~\]-C~12:0~-n-dicarboxylic acid was only to malonyl-CoA without labeling of the acetate moiety of citrate, indicating that oxidation started exclusively in peroxisomes. These results show that pFAO of long-chain acyl-CoA till hexanoyl-CoA contributes to the total oxidative capacity in rat liver and heart. It is not clear from the results how important pFAO is in quantative terms, since the authors did not estimate the total rate of fatty acid oxidation or the turnover of malonyl-CoA. The authors conclude that pFAO supplies acetyl-CoA for malonyl-CoA synthesis and subsequently for lipogenesis. Indeed, Oosterveer et al ([@CR71]) observed label incorporation of \[2-^13^C\]-acetate into palmitate indicating lipogenesis in VLDL in mice during treatment with fibrates, which stimulated mFAO and pFAO.

Wanders et al ([@CR103]) proposed fatty acid ω-oxidation (ωFAO) by the CYP4A/F subfamilies and subsequent peroxisomal oxidation of the resulting dicarboxylic acids as a rescue pathway in mFAO disorders. Jin and coworkers (Jin et al [@CR40]) studied the partitioning of \[U-^13^C\]-C~12~-, \[U-^13^C\]-C~9~-, and \[U-^13^C\]-C~5~-n-dicarboxylic acids over mFAO and pFAO in perfused isolated rat livers by measuring the labeling of various acetyl-CoA proxies. \[U-^13^C\]-C~12:0~-n- and \[U-^13^C\]-C~9:0~-n-dicarboxylic acids were partially oxidized in peroxisomes with terminal oxidation in mitochondria. This is in line with the observation of label transfer of ^13^C from \[1,12-^13^C~2~\]-C~12:0~-n-dicarboxylic acid to malonyl-CoA catalyzed exclusively by peroxisomes. Furthermore, they observed that oxidation of \[U-^13^C\]-C~5:0~-n-dicarboxylic acid (glutaric acid) occurred in mitochondria without a contribution of peroxisomes. As has been noticed above, the authors did not estimate absolute oxidative rates of ωFAO of long-chain fatty acids followed by pFAO of dicarboxylic acids. So, it remains unclear how important these contributions are to the total flux of FAO.

In conclusion, in mice with an mFAO defect, the supply of gluconeogenic substrates appeared to be limited, while the capacity of gluconeogenesis seems not to be affected. Peripheral proteolysis might be too low to supply substrates in adequate amounts. The question arises whether there is a place for a protein-enriched diet in the treatment of mFAO deficiencies. The role of pFAO and ωFAO in patients with a defect in mFAO clearly warrants further study (see Violante et al [@CR100], Wanders et al [@CR104]). The question arises of how important pFAO is in humans in comparison with mFAO. In this respect, the clinical trials with PPARα-ligand benzofibrate are of interest (Bonnefont et al [@CR11]) (Gobin-Limballe et al [@CR24]).

Propionic and methylmalonic aciduria {#Sec15}
------------------------------------

### Propionate metabolism in patients with propionic and methylmalonic aciduria {#Sec16}

The remaining capacity to detoxify propionic acid in patients with PA (MIM\# 606054) or MMA (MIM\# 2510000) had been measured by Thompson and coworkers (Thompson et al [@CR89]) (Thompson et al [@CR88]). In these patients detoxification of propionate is severely hampered due to the deficiency of propionyl-CoA carboxylase (EC\# 6.4.1.3) or methylmalonyl-CoA mutase (EC\# 5.4.99.2). Propionic acid is the product of the oxidation of the amino acids valine, isoleucine, methionine, and threonine; but more importantly, propionic acid is one of the short-chain fatty acids (SCFAs) produced in high amounts by the gut microbiota together with acetate and butyrate (Besten et al [@CR9]). Thompson and coworkers infused three children with PA and three children with MMA with a multi-tracer solution of \[1-^13^C\]-propionate, \[*ring*-^5^H~2~\]-phenylalanine and \[1-^13^C\]-tyrosine. The infusion of \[*ring*-^5^H~2~\]-phenylalanine and \[1-^13^C\]-tyrosine was used to calculate the rate of phenylalanine hydroxylation as a measure of protein catabolism and the rate of irreversible catabolism of the amino acids valine, isoleucine, methionine, and threonine. The appearance rate of propionate into the systemic circulation in the three children with PA was 0.75, 0.76, and 0.82 μmol.kg^−1^.min^−1^ and in the three children with MMA 1.92, 1.45, and 0.77 μmol.kg^−1^.min^−1^. When patients were treated with the antibiotic metronidazole to eliminate propionate production by the gut microbiota, propionate production decreased 22 ± 8%. Very recently Boets et al measured the rate of appearance in the systemic circulation of SCFA in healthy adults (Boets et al). The estimated appearance rate of propionate was 0.27 ± 0.09 μmol.kg^−1^.min^−1^ (*n* = 12) considerably less than in patients with PA and MMA. Next, Thompson and coworkers estimated the oxidation of propionate in the same patients (Thompson et al [@CR89]). In the children with PA, oxidation was 0.18--0.60 μmol.kg^−1^.min^−1^, and in the children with MMA, 0.25--1.08 μmol.kg^−1^.min^−1^. Lower oxidation rates were observed in healthy subjects (0.08--0.32 μmol.kg^−1^.min^−1^). These values were, however, not corrected for differences in circulating propionate concentrations.

### Propionate metabolism in ex vivo models {#Sec17}

Apparently, an alternative pathway for oxidation of propionate might be operative in patients with PA or MMA. In the 1970s Ando et al (Ando et al. [@CR1], Ando et al. [@CR2]) alluded to the possibility of a modified β-oxidation pathway of propionate. Recent studies in *C. elegans* and HepG2 cells (Watson et al [@CR106]) showed the existence of such an alternative oxidation pathway (Fig. [7](#Fig7){ref-type="fig"}). In humans this pathway consists of five enzymes starting at propionyl-CoA dehydrogenation by ACADSB (EC\# 1.3.8.5), hydration of the product acrylyl-CoA by ECHS1 (EC\# 4.2.1), after which the product 3-hydroxypropionyl-CoA is hydrolyzed by HIBCH (EC\# 3.1.2.4) and 3-hydroxypropionate is formed. Further oxidation to malonic semialdehyde is catalyzed by the transhydrogenase ADHFE1 (a.k.a. HOT) (EC\# 1.1.99.24), while reducing 2-ketoglutarate into D-2-hydroxyglutarate. Finally, malonic semialdehyde is oxidative decarboxylated by ALDH6A1 (EC\# 1.2.1.27) into acetyl-CoA and CO~2~.Fig. 7Schematic representation of the two metabolic pathways of propionate in humans. **a** The canonical vitamin B~12~ dependent pathway of propionate conversion into succinate. **b** The modified β-oxidation pathway of propionate with cytotoxic intermediates. MM-methylmalonyl, 3HP-3-hydroxypropionate, MSA-malonic semialdehyde. Source: (Watson et al [@CR106]). *Reproduced with permission from the publisher of eLife journal*

Experiments with \[U-^13^C\]-propionate in the presence and absence of labeled and unlabeled 3-hydropropionate by Wilson and coworkers (Wilson et al [@CR110]) in non-recirculating perfused isolated rat liver were fully compatible with the presence of the proposed modified β-oxidation for propionate. Labeling of 3-hydroxypopionate by \[U-^13^C\]-propionate was almost complete. Appreciable amounts of M~2~ acetyl-CoA were observed indicative of the presence of the modified β-oxidation pathway. As expected, extensive labeling of succinate was also observed via the canonical, vitamin B~12~ dependent pathway, with M~3~ succinate originating from the incorporation of infused M~3~ \[U-^13^C\]-propionate and M~2~ succinate due to recycling of M~3~ succinate through the TCA cycle. The addition of 3-hydroxypropiopnate to the perfusate altered the MID of succinate profoundly. The fractional contribution of M~2~ succinate almost disappeared, pointing to a strong inhibition of the TCA cycle by 3-hydroxypropionate.

In conclusion, the observations made by Thompson and coworkers deserve to be re-investigated in light of these new findings. When one considers stimulation of the modified β oxidation pathway as a therapeutic option in patients with propionic and methylmalonic aciduria, one should realize that intermediates in this pathway are cytotoxic, in contrast to the canonical vitamin B~12~-dependent pathway via methylmalonate and succinate. Appreciable reaction rates will only be obtained at elevated concentrations of propionate such as observed in patients with propionic and methylmalonic aciduria.

Urea cycle defects {#Sec18}
------------------

### Estimation of the urea synthetic flux in vivo in patients with urea cycle defects {#Sec19}

Hepatic urea synthesis is the major pathway by which virtually all terrestrial mammals rid themselves of excess nitrogen. Major sources of nitrogen are portal ammonia derived from host urea hydrolyzed by bacterial urease in the gut, the activity of portal glutaminase, and whole-body amino acid oxidation (Veeneman et al [@CR98]). UCDs come in a wide spectrum of clinical presentations. Hence, it becomes of importance to have a method that estimates the residual activity of the urea cycle when one of the enzymes is deficient. In vivo urea synthesis in healthy subjects and patients with a UCD has been estimated during a primed-continuous intravenous infusion of \[^18^O\]-urea or \[^13^C\]-urea and measurement of isotope dilution of labeled urea in blood. The values obtained for urea synthesis in healthy subjects varied between 3.7 ± 0.2 μmol.kg^−1^.min^−1^ (Matthews and Downey [@CR60]), 2.2 ± 0.3 μmol.kg^−1^.min^−1^ (Lee et al [@CR52]), and 3.6 ± 0.5 μmol.kg^−1^.min^−1^ (Scaglia et al [@CR81]). Our measurements in adult nephrotic patients by a different, kinetic isotopic method gave a value of 3.4 ± 0.2 μmol.kg^−1^.min^−1^ (Veeneman et al [@CR98]). Subsequently, urea synthesis in treated patients had been estimated (Lee et al [@CR52]). In patients with a null mutation of one of the genes encoding for the enzymes of the urea cycle the rate of urea synthesis was not different from 0 μmol.kg^−1^.h^−1^ (−0.01 ± 0.03 μmol.kg^−1^.min^−1^), after correction for urea production of therapeutic arginine and citrulline supplementation. To circumvent this correction the authors used an infusion protocol with \[5-^15^ N\]-glutamine and measured the molar enrichment of \[5-^15^ N\]-glutamine and \[^15^N\]-urea to estimate the transfer of ^15^N from glutamine to urea. They expressed the extent of transfer as a ratio of \[^15^N\]-urea enrichment over \[5-^15^ N\]-glutamine enrichment (Scaglia et al [@CR82], Lee et al [@CR52]). They observed a ratio of 0.42 ± 0.06 in healthy controls, 0.003 ± 0.007 in patients with a null mutation, and intermediate values in the other groups of urea cycle defects (0.16 ± 0.04 to 0.35 ± 0.11). No relation was observed between the severity of the disease in each of the patients individually and their value of the ratio, only groups of patients could be distinguished.

Scaglia and coworkers (Scaglia et al [@CR81]) studied the first pass extraction of orally given ^15^NH~4~Cl in healthy subjects and in female OTC carriers. In healthy subjects 61 ± 8% of the enteral supplied ^15^N was transferred to urea by the liver on the first pass. A total of 17 ± 8% of the orally supplied ^15^N was recovered in glutamine and 22 ± 6% escaped extraction on the first pass by the liver. In female OTC carriers first pass transfer of nitrogen by the liver from orally supplied ^15^NH~4~Cl to urea decreased to 11 ± 8% and the transfer to glutamine increased to 29 ± 8%. A total of 60 ± 6% of enteral ^15^NH~4~Cl escaped the first pass. No difference was observed in the final extent of label incorporation of orally administered tracer into urea between the two groups (81 ± 4% vs 72 ± 4%, mean ± SE, healthy subject vs OCTD carriers, respectively). Next, they studied the effect of phenylbutyrate on nitrogen metabolism in healthy subjects and partial-OTC deficient female subjects. Phenylbutyrate is a drug used in patients suffering from a UCD to induce alternative pathways of nitrogen disposal. All subjects received a phenylbutyrate dose of \~5.6 g.kg^−1^.d^−1^. In control subjects urea synthesis decreased from a mean of 3.0 to 2.6 μmol.kg^−1^.min^−1^ and in partial-OTC deficient female subjects from 2.6 to 2.0 μmol.kg^−1^.min^−1^. Phenylbutyrate did not affect protein catabolism, the whole-body turnover of glutamine, leucine, phenylalanine, and tyrosine nor the hydroxylation of phenylalanine into tyrosine. The clearance of leucine increased by 61% which resulted in a decreased leucine concentration in the bloodstream.

### Tracer-based studies of nitrogen metabolism in model systems {#Sec20}

In the liver an enteral nitrogen load is partitioned over irreversible disposal by the urea cycle and preservation by incorporation of nitrogen into glutamine. Until now most tracer studies with stable isotopes have been performed in non-recirculating perfused isolated liver preparations without a UCD (Brosnan et al [@CR14], Brosnan et al [@CR15], Nissim et al [@CR69], Nissim et al [@CR67], Nissim et al [@CR68], Nissim et al [@CR66]). In urea two N-atoms are present, one derived from NH~3~ and one from aspartate. Accordingly, MIDA was applied to analyze the ^15^N--labeling pattern of urea with \[*ureido*-^15^ N\]-citrulline and \[2-^15^ N\]-aspartate in the effluent as proxies of the immediate precursor enrichment of mitochondrial carbamoylphosphate and cytosolic aspartate, respectively. The transfer of ^15^N to urea was studied from ^15^NH~3~, \[2-^15^ N\]-alanine, and glutamine labeled at the amino-N (\[2-^15^ N\]-glutamine), the amide-N (\[5-^15^ N\]-glutamine) or fully labeled (\[2,5-^15^ N~2~\]-glutamine). Collectively, the studies pointed to the important role of mitochondrial glutamate formation via reductive amination of 2-ketoglutarate by glutamate dehydrogenase in the detoxification of ammonia by supplying aspartate-N for transamination of oxaloacetate into aspartate by glutamate. The amide-^15^ N in \[5-^15^ N\]-glutamine was preferentially transferred to carbamoylphosphate. Furthermore, \[2-^15^ N\]-alanine and ^15^NH~3~ provided both nitrogen-atoms of urea but the transfer of ^15^N via aspartate was preferred by \[2-^15^ N\]-alanine while the transfer via citrulline was preferred by ^15^NH~3~. Perfusion of livers with NH~4~Cl strongly increased the negative nitrogen balance of perfused isolated rat liver indicative of increased hepatic proteolysis to supply enough aspartate-N to the urea cycle. Similar conclusions were reached by Yang et al ([@CR113]) in fasted dogs. Apparently, supply of glutamate by reductive amination of 2-ketoglutarate was inadequate to deal with the high demand of aspartate-N when supply of ammonia was high. Glutamate synthesis in liver mitochondria appeared to be central to ammonia detoxification.

Recent studies by Lamers and coworkers have put the results of these studies in isolated rat liver into a whole body perspective (He et al [@CR28], Hakvoort et al [@CR26]). They studied intestinal ammonia detoxification in control mice and in mice with a liver knockout of glutamine synthetase. They showed that in mice \~30% of the infused ammonia is not cleared by the liver on first pass, independent of portal ammonia concentrations ≤2 mM and an intestinal infusion of ammonia ≤166 μmol NH~4~CO~3~.kg^−1^.min^−1^. Detoxification of the part of intestinal infused ammonia absorbed by the liver (\~70%) was equally partitioned over urea synthesis (\~35%) and glutamine synthesis (\~35%). During an intravenous infusion of NH~4~CO~3~, detoxification of systemic ammonia was almost entirely dependent on glutamine synthesis in muscle at an infusion rate ≤ 20 μmol NH~4~CO~3~.kg^−1^.min^−1^. Next, the transfer of the amide-N of glutamine to urea was studied in control mice and mice with liver and muscle knockout of glutamine synthetase using a multi tracer primed-continuous infusion protocol with \[5-^15^ N\]-glutamine and \[^18^O,^15^N~2~\]-urea and the measurement of the dilution of \[5-^15^ N\]-glutamine and \[^18^O,^15^N~2~\]-urea and the appearance of \[^15^N\]-urea in the circulation. The whole-body rate of appearance of newly synthesized glutamine, traced with \[5-^15^ N\]-glutamine, was closely correlated with the rate of transfer of amide-N of newly synthesized glutamine to urea (measured as \[^15^N\]-urea), without changes in total urea production, measured with \[^18^O,^15^N~2~\]-urea. These studies clearly point to the pivotal role of glutamine in whole body nitrogen metabolism.

Marini and coworkers (Matini et al [@CR59], Marini et al [@CR56], Marini et al [@CR57]) studied urea synthesis in wild-type mice and in mice hypomophic for ornithine transcarbamoyltransferase (EC\# 2.1.3.3) (OTC^spf-ash^). In normal mice they measured urea synthesis by isotope dilution of a single intravenous bolus injection of \[^15^N~2~\]-urea and by primed continuous intravenous infusion of the same label. The rate of urea synthesis was 56 ± 12 μmol.kg^−1^.min^−1^ an order of magnitude greater than reported in humans. Urea synthesis in OTC^spf-ash^ mice was not different from control mice (52 ± 11 μmol.kg^−1^.min^−1^). When control mice and OTC^spf-ash^ mice were fed a complete mixture of amino acids at \~200 μat N.kg^−1^.min^−1^, no difference was observed in the ability to synthesize urea (mean: 107 vs 108 μmol.kg^−1^.min^−1^, control vs OTC^spf-ash^ mice, respectively). In contrast, when OTC^spf-ash^ mice were fed an unbalanced mixture of glycine and alanine at a molar ratio of 1:2 without other amino acids, at \~200 μat N.kg^−1^.min^−1^ no increase was observed in urea synthesis (mean: 71 vs 53 μmol.kg^−1^.min^−1^, control vs OTC^spf-ash^ mice). When OTC^spf-ash^ mice fed the glycine-alanine mixture were intravenously infused with ornithine at 53 μmol.kg^−1^.min^−1^ urea synthesis normalized (mean: 75 vs 76 μmol.kg^−1^.min^−1^, control vs OTC^spf-ash^ mice). Apparently, the complete mixture of amino acids generated enough ornithine to allow OTC^spf-ash^ mice to cope with the increased nitrogen load of the complete mixture of amino acid. We can compare this outcome with results of experiments where the effect was studied of  perfusion of isolated rat liver with a solution of NH~4~Cl (see above). Liver weight decreased and the conclusion was drawn that protein catabolism was enhanced to supply adequate amounts of aspartate-N to detoxify ammonia. The experiments in OTC^spf-ash^ mice point to the importance of the supply of ornithine or of its precursor arginine when the urea cycle is 'broken'. For some UCDs this is part of the clinical management of patients.

In conclusion, not all ammonia supplied by the gut is converted into urea upon first pass by the liver. The remainder is transferred to glutamine or enters the systemic circulation where glutamine synthesis in peripheral tissue transfers ammonia-N to glutamine. The supply of 2-ketoglutarate in liver mitochondria plays an important role to supply glutamate. Newly synthesized glutamine from glutamate is a major precursor of urea synthesis. The study of whole-body nitrogen metabolism in models of UCDs holds the key to new modalities of treatment of these patients as is already shown by the studies in OTC^spf-ash^ mice. One might hypothesize that supplying precursors of glutamine synthesis alleviates the hyperammonemia (Hakvoort et al [@CR26]). Moreover, oral supplementation with ornithine might also alleviate or even prevent hyperammonemic periods, particularly for female OTC carriers.

Phenylketonuria {#Sec21}
---------------

In three studies the residual activity of phenylalanine hydroxylation was measured in PKU patients (MIM\# 261600) (Thompson et al [@CR89]; Thompson and Halliday [@CR87]; van Spronsen et al [@CR96]). In PKU patients the enzyme that converts phenylalanine into tyrosine (phenylalanine 4-monooxygenase (EC 1.14.16.1)) is deficient. A multi tracer primed-continuous infusion of a solution of \[*phenyl-*^2^H~5~\]-phenylalanine and \[1-^13^C\]-tyrosine was given to PKU patients and during infusion blood samples were drawn. Isotope dilution was measured of \[*phenyl-*^2^H~5~\]-phenylalanine, \[1-^13^C\]-tyrosine, and \[*phenyl-*^2^H~4~\]-tyrosine, the hydroxylation product of \[*phenyl-*^2^H~5~\]-phenylalanine. Thompson and coworkers (Thompson and Halliday [@CR87], Thompson et al [@CR89]) observed an almost normal rate of hydroxylation of phenylalanine in PKU patients of 0.08 ± 0.04 μmol.kg^−1^.min^−1^, compared to healthy subjects 0.10 ± 0.03 μmol.kg^−1^.min^−1^. In two patients with hyperphenylalaninemia, hydroxylation of phenylalanine was 0.07 and 0.09 μmol.kg^−1^.min^−1^. No relationship was observed between the apparent rate of hydroxylation and the concentration of phenyalanine in blood during the study. Applying the same experimental protocol Van Spronsen et al came to a completely different conclusion (van Spronsen et al [@CR96]). In PKU patients they estimated the rate of phenylalanine hydroxylation to be 0.006 ± 0.002 μmol.kg^−1^.min^−1^. Their values in two healthy subjects were 0.10 and 0.07 μmol.kg^−1^.min^−1^, fully compatible with the values observed by Thompson and coworkers. No relation was found between the hydroxylation rate and the tolerance to natural protein in the diet. The reason for the lack of correlation of phenylalanine hydroxylation and measures of clinical severity is not clear. It might be that other as yet unknown pathways exist which metabolize phenylalanine. Bacterial metabolism might have interfered with the measurements of phenylalanine metabolism. To a certain extent, this might be similar to the case of host urea, which is hydrolyzed in the intestine by bacterial urease. When \[^2^H~5~\]-phenylalanine is hydrolyzed by bacterial phenylalanine ammonia lyase (EC 4.3.1.24) it escapes conversion into tyrosine (Clayton [@CR18]). In this way phenylalanine leaves the circulation by two routes, and only one is traced by the experimental set up.

Tracer-based studies of citrate metabolism in fibroblasts of patients with combined D,L-2-hydroxyglutaric aciduria {#Sec22}
------------------------------------------------------------------------------------------------------------------

The group of Struys studied metabolic reprogramming in fibroblasts of patients lacking the citrate transporter (unpublished observations). Deficiency of the mitochondrial citrate transporter (SLC25A1) results in combined D- and L-2-hydroxyglutaric aciduria (MIM\#615182) (Nota et al [@CR70]). Citrate is central to TCA cycle and it caries acetyl-units generated by pyruvate dehydrogenase or fatty acid oxidation from the mitochondrial matrix into the cytosol to supply acetyl-CoA to de novo lipogenesis, cholesterol synthesis (Fig. [8](#Fig8){ref-type="fig"}a, b) and histone acetylation (Wellen et al [@CR109]). Control and patient fibroblasts were incubated with M~5~ \[U-^13^C\]-glutamine. Conversion of the carbon skeleton of glutamine into citrate proceeds partly in the mitochondrion and partly in the cytosol via successive deamidation and deamination of glutamine to 2-oxoglutarate in mitochondria and reductive carboxylation of 2-oxoglutarate to isocitrate catalyzed by cytosolic isocitrate dehydrogenase 1 (Mullen et al [@CR64]) (Metallo et al [@CR62]). In control fibroblasts, a prominent fractional contribution of M~4~ citrate to the MID of citrate was observed. Mitochondrial M~5~ 2-oxoglutarate from M~5~ \[U-^13^C\]-glutamine is converted into M~4~-oxaloacetate by the TCA cycle. Furthermore, cytosolic M~5~ citrate from M~5~ \[U-^13^C\]-glutamine enters the mitochondria and is also converted into M~4~ oxaloacetate (Fig. [8](#Fig8){ref-type="fig"}b). Very little M~5~ citrate was observed in control fibroblasts. In patient fibroblasts, however, a high fractional contribution of M~5~ citrate to the MID of citrate was observed, confirming the severely impaired entrance of cytosolic citrate into mitochondria in patient fibroblast for further oxidation.Fig. 8Schematic representation of TCA cycle and cytosolic metabolism of TCA intermediates. **a** Schematic representation of mitochondrial (m) and cytosolic (c) citrate metabolism and carbon atom transitions for \[U-^13^C\]-glucose (**b**) idem for \[U-^13^C\]-glutamine. Black circles represents aliphatic atoms, red circle represents carboxylic carbon atoms. Open circles represent unlabeled carbon atoms. Closed circles represent ^13^C labeled carbon atoms. Glc -- glucose, Pyr -- pyruvate, Ac -- acetylCoA, Cit -- citrate, Isocit -- isocitrate, αOG -- 2-ketoglutarate, Suc -- succinate, Fum -- fumarate, Mal -- malate, Oxac -- oxaloacetate, E-glutamate, Q-glutamine

Next, the fate of the label was followed into cholesterol, a kind of '13/14-polymer' of acetate (Hellerstein and Neese [@CR30]; Kelleher et al [@CR47]). Acetate used in the cholesterol synthesis comes partially from citrate. Labeling of citrate by acetate coming from \[U-^13^C\]-glucose takes place inside mitochondria and labeled citrate needs to be exported to provide acetate for the cholesterol biosynthesis (Fig. [8](#Fig8){ref-type="fig"}a). When control fibroblasts were incubated with \[U-^13^C\]-glucose the fractional contribution of M~6~--M~10~ mass isotopomers dominated the MID of cholesterol, indicative of considerable labeling of acetate pool. In patient fibroblasts a shift was observed to lower mass isotopomers of cholesterol indicative of less efficient labeling of acetate. The transport of mitochondrial labeled citrate to the cytosol was severely impaired when SLC25A1 is deficient.

Synthesis of citrate from glutamine takes place in the cytosol by reductive carboxylation of 2-ketoglutarate (Fig. [8](#Fig8){ref-type="fig"}b). M~5~ \[U-^13^C\]-glutamine gives rise to M~5~ citrate in the cytosol, which is split into M~3~ oxaloacetate and M~2~ acetyl-CoA by ATP-citrate lyase. When control fibroblasts were incubated with \[U-^13^C\]-glutamine a minor contribution of M~2~ cholesterol was observed. Apparently, in control fibroblasts glutamine-derived acetyl-CoA is of very limited importance in the supply of acetate to cholesterol biosynthesis. In patient fibroblast, however, the picture was quite different with an increased fraction of M~4~ cholesterol, indicative for a more prominent labeling of acetyl-CoA by \[U-^13^C\]-glutamine. In the absence of the mitochondrial citrate transporter glutamine became a donor of acetate-units to cholesterol synthesis.

The results of this study are very similar to those obtained in the lung tumor cell line H460 (Jiang et al [@CR38]). SLC25A1 has been implicated in tumor progression (Kolukula et al [@CR50], Catalina-Rodriguez et al [@CR17]). Among other things, Jiang et al studied the transfer of ^13^C from \[U-^13^C\]-glucose and \[U-^13^C\]-glutamine to palmitate, the 'octamer' of the monomer acetate. After incubation of H460 cells with \[U-^13^C\]-glucose palmitate MID was dominated by M~10~--M~16~ mass isotopomers, indicative of a high flux of M~2~ citrate from the mitochondria into the cytosol resulting in a very efficient labeling of the cytosolic acetate pool. Deletion of SLC25A1 by CRISPR/Cas9 shifted the fractional contribution of the dominant mass isotopomers of the MID of palmitate to lower mass isotopomers (M~2~--M~8~), reflecting a restricted efflux of M~2~ citrate from mitochondria into the cytosol with a lower efficiency of labeling of the acetate pool for palmitate biosynthesis. When H460 cells were incubated with \[U-^13^C\]-glutamine, only M~2~--M~4~ mass isotopomers were observed in the MID of palmitate. After deletion of SLC25A1 labeling efficiency of acetate by \[U-^13^C\]-glutamine increased, with M~6~--M~10~ as the dominant mass isotopomers of palmitate.

Conclusions and future perspectives {#Sec23}
===================================

In Table [1](#Tab1){ref-type="table"} an overview is given of the major results and possible therapeutic consequences of the studies on metabolic reprogramming in patients with an IEM and related model systems with stable isotopes. The summary clearly shows that whole body metabolism adapts in a way which was quite unexpected and which was very specific for each of the IEMs individually. It clearly points to the need of in vivo studies both in patients and in animal models of IEM.Table 1Summary of results of flux analysis in IEMIEMResultsGSD Ia- Appreciable postprandial glucose production\
- Glucose production is due to glucosidase activity in liver\
- Intracellular de novo lipid metabolism is strongly enhanced\
- Lipoprotein metabolism seems to be impaired with reduced lipolysis\
- Metabolic reprogramming is driven by the transcription factor ChREBP activated by G6PMCADD- Normal oxidation of medium-chain fatty acids.\
- The hypoglycemia is driven by a persistent increased consumption of glucose by peripheral tissue and an inadequate production of glucose by gluconeogenesis\
- Supply of gluconeogenic substrates by peripheral tissue might be too low.\
- A protein-enriched diet might be an additional therapeutic option for patient with MCADD to boost gluconeogenesis to prevent a hypoglycemic hypoketotic crisis.\
- There might be an additional role of peroxisomes and endoplasmic reticulum to fatty acid oxidationPMA- Propionate oxidation is almost higher in patients with PMA than in healthy volunteers\
- Gut microbiota are an important producer of propionate\
- A modified β oxidation pathway of propionate exists in humans, with cytotoxic intermediates\
- Changing the microbiota composition by dietary intervention might be a therapeutic optionUCD- First pass absorption by the liver of ammonia from the gut is \~70% and 30% enters the systemic circulation.\
- Direct conversion of ammonia into urea upon first pass is limited to 35% of the supplied ammonia.\
- Remainder of supplied ammonia is used in the synthesis of glutamine, in liver and in muscle\
- Glutamine is central in whole body nitrogen metabolism and in urea synthesis\
- 2-Ketoglutarate supply in hepatic mitochondria is an important precursor in whole body glutamate and glutamine synthesis\
- Additional gifts of glutamate to enhance glutamine synthesis during hyperammonemic events might be an additional therapeutic option\
- Re-interpretation of changes in glutamine concentration in blood during the monitoring of therapy might be necessaryPKU- There is an as yet unidentified pathway of phenylalanine oxidation.D,L-2OHG-uria- Preliminary results in fibroblast point to a shift from glucose to glutamine to support lipid and cholesterol synthesis

Besides studying reprogrammed metabolism, it also became clear that the study of the role of gut microbiota in the clinical presentation of IEMs urgently needs closer examination. In mFAO the rate of microbial synthesis of products like arylcarboxylates, in PA and MMA of SCFA, and in UCDs of ammonia might be of importance to understand the broad spectrum of clinical presentation of IEMs. There are ample studies showing that both human genetic variation and diet have clear effects on the composition of the gut microbiota, predisposing to microbiome dysbiosis (see (Hall et al [@CR27]) for a review). It can be expected that also in the case of IEM, microbiome composition is altered and possibly leads to microbiome dysbiosis.

In only a limited set of IEM extensive studies have been performed. More model systems are required to address the many issues in the pathology of IEMs. Genetically modified mice are the main model system, but they have their drawbacks. A clear example is the GALT knockout mice model for galactosemia, which did not show the clinical phenotype seen in children suffering from galactosemia (Leslie et al [@CR55]). The use of zebrafish as an alternative to mice is an emergent field (Wager et al [@CR101]). New cell models and methods offer new opportunities for the study of IEM (Wangler et al [@CR105]).

Great progress has been made in the development of induced specific cell types starting from patient fibroblasts (Xu et al [@CR112]). New methods in tracer-based metabolomics allows for fingerprinting of metabolism with unsupervised non-targeted tracer fate detection (Hiller et al [@CR34]; Weindl et al [@CR108]). Mathematical models are continuously being improved to convert the observed MIDs of metabolites into flux pattern (for reviews see (Buescher et al [@CR16]; Vasilakou et al [@CR97])).

In tumors, metabolism is also forced to reprogram itself because of mutations in genes coding for proteins involved in cellular growth and associated metabolism. Sometimes, enzyme deficiencies known in the field of IEMs results in tumor formation, showing the overlap of both fields with respect to the many ways metabolism can reorganize itself (see (Erez and DeBerardinis [@CR22]; DeBerardinis and Thompson [@CR19]) for reviews). Many metabolic studies in tumors testify to the extreme versatility of metabolism to sustain maintenance and growth of cells (see (Wong et al [@CR111]) for a review).

Systems biology might offer a new way to integrate multi-omics data into molecular networks (Argmann et al [@CR3]). Recently, a community-driven global reconstruction of human metabolism resulted in the comprehensive genome-scale metabolic map Recon 2 (Thiele et al [@CR86]). This metabolic map has already been used to predict additional metabolic biomarkers of IEMs (Sahoo et al [@CR80]; Thiele et al [@CR86]; Shlomi et al [@CR83]). One might use this map not only to predict biomarkers but also to diagnose as yet unknown inborn errors of metabolism by projecting abnormal metabolite profiles and genome-wide exome sequence data onto this map. This is now actively pursued in the Undiagnosed Diseases Network in the USA and internationally (Taruscio et al [@CR85]; Ramoni et al [@CR74]; Austin et al [@CR5]). The map can also be used to elucidate affected pathways in known inborn errors of metabolism. In this way the targeted approach applied for instance in the study of lysine metabolism (Struys and Jakobs [@CR84]; Posset et al [@CR72]) to elucidate defective metabolic pathways, can now be transformed into a genomic-wide approach. Very recently, a systems biology approach has been undertaken to integrate Recon-2 with metabolomics data of the NCI-60 panel of 60 well characterized primary human cancer cell lines established from nine common tumor types (Jain et al [@CR37], Aurich et al [@CR4]). The results of extracellular metabolomics reflecting uptake and release of metabolites were used to generate condition- and cell-specific metabolic models of the cancer cell lines. Next, these metabolic models were analyzed for their capability to harvest energy and generate cofactors. This analysis revealed the different strategies cells can use to cope with environmental and genetic perturbations. Stable isotope based metabolomics can then be used to test the hypotheses generated. This looks a very promising way to study metabolic reprogramming of patient fibroblasts or fibroblast-derived induced specific cell types.

Textbook knowledge is clearly insufficient to deduce the way metabolism copes with an enzyme deficiency. Metabolism and its regulation appear to be too versatile. Methods are now available to generate hypotheses about the flux distribution in the case of IEMs on a genome-wide scale and cell specific. Stable isotopes methodology is the tool to test these hypotheses. Hopefully, these new technologies will help us to get a better understanding of how metabolism is reprogrammed in patients with an IEM such that we are able to offer these patients better treatments for a better life.
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